Disappointing late-stage findings marred the prospects for Alder BioPharmaceuticals' experimental migraine treatment, reported.
The CGRP-inhibitor treatment eptinezumab provided a relatively small decrease in average migraine days. Those on 100 mg of the infusion drug reported a mean decrease of about 3.9 migraine days per month, while those on 300 mg experienced 4.3 fewer migraine days. These decreases did not differ markedly from the 3.2-day reduction obtained with placebo.
Although Adler said the findings met the study's primary goal, recent reports from competitors have also reported positive late-stage findings for similar agents, Reuters noted.